Acute pro‑B‑Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review

Abstract

The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S1231F) of the additional sex combs like 1, transcriptional regulator gene was identified, which may have a substantial role in the progression, however does not act as an unfavorable prognostic marker. The patient died during induction chemotherapy. The present study further conducted an analysis on 30 patients to determine progression to ALL. Patients were predominantly male (76.7%, 23/30) with a median age of 56 years (3–90 years). The median time to transformation was 5.5 months (2–50 months). The most common type of MDS with ALL transformation comprised of MDS-excess blasts (MDS-EB; 40%, 12/30), MDS with single-lineage dysplasia (MDS-SLD; 30%, 9/30) and MDS with ring sideroblasts (MDS-RS; 16.7%, 5/30). The majority of the patients transformed to B-cell (66.7%, 16/24) followed by T-cell (33.3%, 8/24) ALL. From the 25 cases where data was available, the complete remission rate was 75% (15/20) with ALL-directed chemotherapy and the median remission duration was 15 months (range 4.5 to 51 months). However, the results indicated that ALL following MDS is characterized by a high rate of early death (20%, 5/25).

Progression in Myeloid Neoplasms: Beyond the Myeloblast

“…Pathobiology 2024;91:55-75 DOI: 10.1159/000530940 [7,[107][108][109][110][111][112][113], with some cases showing molecularly proven common clonal origin with shared recurrent genetic aberrations. Recently, a case of B-LB transformation of an MPN with BCR::JAK2-fusion has been molecularly dissected [114], highlighting the central role of IKZF1 deletion and consequent upregulation of IL7R and CRLF2 (with IKZF1 being the negative regulator of both genes), as well as the final adaptation to an activated B-cell receptor-like signaling phenotype, with upregulation of CD79A, CD79B, IGLL1, VPREB1, BLNK, ZAP70, RAG1, and RAG2.…”